Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Cash from Operations for 9 consecutive years, with 65925000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Operations rose 23.67% year-over-year to 65925000.0; the TTM value through Mar 2026 reached 229230000.0, down 27.19%, while the annual FY2025 figure was 249675000.0, 51.57% down from the prior year.
  • Cash from Operations hit 65925000.0 in Q1 2026 for Bicycle Therapeutics, down from 19346000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 34096000.0 in Q2 2023 and bottomed at 86370000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 36886058.82, with a median of 39832000.0 recorded in 2024.
  • Year-over-year, Cash from Operations soared 244.9% in 2023 and then tumbled 3786.05% in 2024.
  • Bicycle Therapeutics' Cash from Operations stood at 30309000.0 in 2022, then crashed by 56.02% to 47288000.0 in 2023, then skyrocketed by 80.13% to 9396000.0 in 2024, then tumbled by 105.9% to 19346000.0 in 2025, then crashed by 240.77% to 65925000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 65925000.0, 19346000.0, and 71173000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.